Advertisement

The U.S. Food and Drug Administration has granted 510(k) marketing clearance for Tomophase Corp.’s non-invasive Optical Coherence Tomography Imaging System (OCTIS), according to a news release from the company.

Tomophase makes imaging systems for interventional pulmonology that are designed to help diagnose lung cancer, asthma and other pulmonary conditions. The OCTIS will be used at first for imaging lung tissue and the airways; it will ultimately include imaging applications in diagnostic and therapeutic uses.

SOURCE

Advertisement
Advertisement